SLC6A14 and cancer: Wnt signaling was reported to be involved in cancer progression, since SLC6A14 expression was shown to be reduced by silencing of β-catenin with shRNA and incubation of cancer cells with Wnt antagonist, while an opposite effect was observed after Wnt agonist treatment and β - catenin overexpression (Sikder et al., 2020).